| advertise add site services publishers database health videos | ![]() | about toolbar stats live show health store more stuff JOIN/LOGIN |
Drug Discovery Chemistry 2007 - G-Protein Coupled Receptor Drug... chidb.com | differentiation sphingolipid G-protein-coupled receptor 5 (EDG5)... biocarta.com |
"GPCR" redirects here. For the Great Proletarian Cultural Revolution, see Cultural Revolution. A Mu-opioid G-protein-coupled receptor with its agonist G protein-coupled receptors (GPCRs), also known as seven-transmembrane domain receptors, 7TM receptors, heptahelical receptors, serpentine receptor, and G protein-linked receptors (GPLR), comprise a large protein family of transmembrane receptors that sense molecules outside the cell and activate inside signal transduction pathways and, ultimately, cellular responses. G protein-coupled receptors are found only in eukaryotes, including yeast, choanoflagellates[1], and animals. The ligands that bind and activate these receptors include light-sensitive compounds, odors, pheromones, hormones, and neurotransmitters, and vary in size from small molecules to peptides to large proteins. G protein-coupled receptors are involved in many diseases, and are also the target of around half of all modern medicinal drugs.[2] There are two principal signal transduction pathways involving the G-protein coupled receptors: the cAMP signal pathway and the Phosphatidylinositol signal pathway.[3] When a ligand binds to the GPCR it causes a conformational change in the GPCR which allows it to act as a guanine nucleotide exchange factor (GEF). The GPCR can then activate an associated G-protein by exchanging its bound GDP for a GTP. The G-protein's α subunit, together with the bound GTP, can then dissociate from the β and γ subunits to further affect intracellular signaling proteins or target functional proteins directly depending on the α subunit type (Gαs ,Gαi, Gαq/11, Gα12/13).
[edit] ClassificationGPCRs can be grouped into 6 classes based on sequence homology and functional similarity:[4][5][6][7]
The very large rhodopsin A group has been further subdivided into 19 subgroups (A1-A19).[8] More recently, an alternative classification system called GRAFS (Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, Secretin) has been proposed.[9] The human genome encodes thousands of G protein-coupled receptors,[10] about 350 of which detect hormones, growth factors, and other endogenous ligands. Approximately 150 of the GPCRs found in the human genome have unknown functions. [edit] Physiological rolesGPCRs are involved in a wide variety of physiological processes. Some examples of their physiological roles include:
[edit] Receptor structureGPCRs are integral membrane proteins that possess seven membrane-spanning domains or transmembrane helices (Figure 1). The extracellular parts of the receptor can be glycosylated. These extracellular loops also contain two highly-conserved cysteine residues that form disulfide bonds to stabilize the receptor structure. Some seven-transmembrane helix proteins (channelrhodopsin) that resemble GPCRs may contain ion channels, within their protein. Early structural models for GPCRs were based on their weak analogy to bacteriorhodopsin, for which a structure had been determined by both electron diffraction (PDB 2BRD, 1AT9)[11][12] and X ray-based crystallography (1AP9).[13] In 2000, the first crystal structure of a mammalian GPCR, that of bovine rhodopsin (1F88), was solved.[14] While the main feature, the seven transmembrane helices, is conserved, the relative orientation of the helices differ significantly from that of bacteriorhodopsin. In 2007, the first structure of a human GPCR was solved (2R4R, 2R4S).[15] This was followed immediately by a higher resolution structure of the same receptor (2RH1).[16][17] This human β2-adrenergic receptor GPCR structure, proved to be highly similar to the bovine rhodopsin in terms of the relative orientation of the seven-transmembrane helices. However the conformation of the second extracellular loop is entirely different between the two structures. Since this loop constitutes the "lid" that covers the top of the ligand binding site, this conformational difference highlights the difficulties in constructing homology models of other GPCRs based only on the rhodopsin structure. [edit] MechanismThe G protein-coupled receptor is activated by an external signal in the form of a ligand or other signal mediator. This creates a conformational change in the receptor, causing activation of a G protein. Further effect depends on the type of G protein. [edit] Ligand bindingGPCRs include receptors for sensory signal mediators (e.g., light and olfactory stimulatory molecules); adenosine, bombesin, bradykinin, endothelin, γ-aminobutyric acid (GABA), hepatocyte growth factor, melanocortins, neuropeptide Y, opioid peptides, opsins, somatostatin, tachykinins, vasoactive intestinal polypeptide family, and vasopressin; biogenic amines (e.g., dopamine, epinephrine, norepinephrine, histamine, glutamate (metabotropic effect), glucagon, acetylcholine (muscarinic effect), and serotonin); chemokines; lipid mediators of inflammation (e.g., prostaglandins, prostanoids, platelet-activating factor, and leukotrienes); and peptide hormones (e.g., calcitonin, C5a anaphylatoxin, follicle-stimulating hormone (FSH), gonadotropic-releasing hormone (GnRH), neurokinin, thyrotropin-releasing hormone (TRH), and oxytocin). GPCRs that act as receptors for stimuli that have not yet been identified are known as orphan receptors. Whereas, in other types of receptors that have been studied, ligands bind externally to the membrane, the ligands of GPCRs typically bind within the transmembrane domain. However, Protease-activated receptors are activate by cleavage of part of their extracellular domain.[18] [edit] Conformational changeThe transduction of the signal through the membrane by the receptor is not completely understood. It is known that the inactive G protein is bound to the receptor in its inactive state. Once the ligand is recognized, the receptor shifts conformation and, thus, mechanically activates the G protein, which detaches from the receptor. The receptor can now either activate another G protein or switch back to its inactive state. This is an overly simplistic explanation, but suffices to convey the overall set of events. It is believed that a receptor molecule exists in a conformational equilibrium between active and inactive biophysical states.[19] The binding of ligands to the receptor may shift the equilibrium toward the active receptor states.[20] Three types of ligands exist: Agonists are ligands that shift the equilibrium in favour of active states; inverse agonists are ligands that shift the equilibrium in favour of inactive states; and neutral antagonists are ligands that do not affect the equilibrium. It is not yet known how exactly the active and inactive states differ from each other. [edit] Activation of G proteinSee also: G protein If a receptor in an active state encounters a G protein, it may activate it (Figure 2, blue protein in part B). Some evidence suggests that receptors and G proteins are actually pre-coupled. For example, binding of G proteins to receptors affects the receptor's affinity for ligands. Activated G proteins are bound to GTP. Further signal transduction depends on the type of G protein. The enzyme adenylate cyclase (Figure 2, green protein in panel C) is an example of a cellular protein that can be regulated by a G protein, in this case the G protein Gs. Adenylate cyclase activity is activated when it binds to a subunit of the activated G protein (Figure 2, Panel D). Activation of adenylate cyclase ends when the G protein returns to the GDP-bound state (Figure 2, panels E and A). Adenylate cyclases (of which 9 membrane bound and one cytosolic forms are known in humans) may also be activated or inhibited in other ways (e.g. Ca2+/Calmodulin binding) and that this can modify the activity of these enzymes in an additive or synergistic fashion along with the G proteins. [edit] GPCR signaling without G proteinsIn the late 1990s, evidence began accumulating to suggest that some GPCRs are able to signal without G proteins. The ERK2 mitogen-activated protein kinase, a key signal transduction mediator downstream of receptor activation in many pathways, has been shown to be activated in response to cAMP-mediated receptor activation in the slime mold D. discoideum despite the absence of the associated G protein α- and β-subunits. In mammalian cells, the much-studied β2-adrenoceptor has been demonstrated to activate the ERK2 pathway after arrestin-mediated uncoupling of G-protein-mediated signaling. Therefore it seems likely that some mechanisms previously believed to be purely related to receptor desensitisation are actually examples of receptors switching their signaling pathway rather than simply being switched off. In kidney cells, the bradykinin receptor B2 has been shown to interact directly with a protein tyrosine phosphatase. The presence of a tyrosine-phosphorylated ITIM (immunoreceptor tyrosine-based inhibitory motif) sequence in the B2 receptor is necessary to mediate this interaction and subsequently the antiproliferative effect of bradykinin.[21] [edit] Two principal pathwaysThere are two principal signal transduction pathways involving the G-protein linked receptors: cAMP signal pathway and Phosphatidylinositol signal pathway.[22] [edit] cAMP signal pathwayThe cAMP signal transduction contains 5 main characters: stimulative hormone receptor (Rs) or inhibitory hormone receptor (Ri);Stimulative regulative G-protein (Gs) or inhibitory regulative G-protein (Gi);Adenylyl cyclase; Protein Kinase A (PKA); and cAMP phosphodiesterase. Stimulative hormone receptor (Rs) is a receptor that can bind with stimulative signal molecules, while inhibitory hormone (Ri) is a receptor that can bind with inhibitory signal molecules. Stimulative regulative G-protein is a G-protein linked to stimulative hormone receptor (Rs) and its α subunit upon activation could stimulate the activity of an enzyme or other intracellular metabolism. On the contrary, inhibitory regulative G-protein is linked to an inhibitory hormone receptor and its α subunit upon activation could inhibit the activity of an enzyme or other intracellular metabolism. The Adenylyl cyclase is a 12 transmembrane glucoprotein that catalyzes ATP to form cAMP with the help of cofactor Mg2+ or Mn2+. The cAMP produced is a second messenger in cellular metabolism and is an allosteric activator to Protein kinase A. Protein kinase A is an important enzyme in cell metabolism due to its ability to regulate cell metabolism by phosphorylating specific committed enzymes in the matabolic pathway and it can also regulate specific gene expression, cellular secretion and membrane permeability. The protein enzyme contains two catalytic subunits and two regulatory subunits. When there is no cAMP,the complex is inactive. When cAMP binds to the regulatory subunits, their conformation is altered, causing the dissociation of the regulatory subunits, which activates protein kinase A and allows further biological effects. cAMP phosphodiesterase is an enzyme that can degrade cAMP to 5'-AMP, which will terminate the signal. [edit] Phosphatidylinositol signal pathwayIn the phosphatidylinositol signal pathway, the extracellular signal molecule binds with the G-protein receptor (Gq) on the cell surface and activates phospholipase C, which is located on the plasma membrane. The lipase hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into two second messengers: Inositol 1,4,5-triphosphate (IP3) and Diacylglycerol (DAG). IP3 binds with the receptor in the membrane of the smooth endoplasmic reticulum and mitochondria, help open the Ca2+ channel. DAG will help activate Protein Kinase C (PKC), which phosphorylates many other proteins, changing their catalytic activities, leading to cellular responses. The effects of Ca2+ is also remarkable: it cooperates with DAG in activating PKC and can activate CaM kinase pathway, in which calcium modulated protein calmodulin (CaM) binds Ca2+, undergoes a change in conformation, and activates CaM kinase II, which has unique ability to increase its binding affinity to CaM by autophosphorylation, making CaM unavailable for the activation of other enzymes. The kinase then phosphorylates target enzymes, regulating their activities. The two signal pathways are connected together by Ca2+-CaM, which is also a regulatory subunit of adenylyl cyclase and phosphodiesterase in cAMP signal pathway. [edit] Receptor regulationGPCRs become desensitized when exposed to their ligand for a prolonged period of time. There are two recognized forms of desensitization: 1) homologous desensitization, in which the activated GPCR is downregulated; and 2) heterologous desensitization, wherein the activated GPCR causes downregulation of a different GPCR. The key reaction of this downregulation is the phosphorylation of the intracellular (or cytoplasmic) receptor domain by protein kinases. [edit] Phosphorylation by cAMP-dependent protein kinasesCyclic AMP-dependent protein kinases (protein kinase A) are activated by the signal chain coming from the G protein (that was activated by the receptor) via adenylate cyclase and cyclic AMP (cAMP). In a feedback mechanism, these activated kinases phosphorylate the receptor. The longer the receptor remains active, the more kinases are activated, the more receptors are phosphorylated. In β2-adrenoceptors, this phosphorylation results in the switching of the coupling from the Gs class of G-protein to the Gi class. [23] cAMP-dependent PKA mediated phosphorylation can cause heterologous desensitisation in receptors other than those activated.[24] [edit] Phosphorylation by GRKsThe G protein-coupled receptor kinases (GRKs) are protein kinases that phosphorylate only active GPCRs. Phosphorylation of the receptor can have two consequences:
[edit] Receptor oligomerizationIt is generally accepted that G-protein-coupled receptors can form heteromers such as homo- and heterodimers as well as more complex oligomeric structures, and indeed heterodimerization has been shown to be essential for the function of receptors such as the metabotropic GABA(B) receptors. However, it is presently unproven that true heterodimers exist. Present biochemical and physical techniques lack the resolution to differentiate between distinct homodimers assembled into an oligomer or true 1:1 heterodimers. It is also unclear what the functional significance of oligomerization might be, although it is thought that the phenomenon may contribute to the pharmacological heterogeneity of GPCRs in a manner not previously anticipated. This is an actively-studied area in GPCR research. The best-studied example of receptor oligomerisation are the metabotropic GABAB receptors. These receptors are formed by heterodimerization of GABABR1 and GABABR2 subunits. Expression of the GABABR1 without the GABABR2 in heterologous systems leads to retention of the subunit in the endoplasmic reticulum. Expression of the GABABR2 subunit alone, meanwhile, leads to surface expression of the subunit, although with no functional activity (i.e., the receptor does not bind agonist and cannot initiate a response following exposure to agonist). Expression of the two subunits together leads to plasma membrane expression of functional receptor. It has been shown that GABABR2 binding to GABABR1 causes masking of a retention signal[28] of functional receptors.[29] [edit] DictyosteliumA novel GPCR containing a lipid kinase domain has recently been identified in Dictyostelium that regulates cell density sensing.[30] [edit] References
[edit] See also[edit] External links
| ||||||||||||||||||||||||||||||||||||||||||||||||||
| ↑ top of page ↑ | about thumbshots |